WO2015054976A1 - 布瑞哌唑、其关键中间体及其盐的制备方法 - Google Patents
布瑞哌唑、其关键中间体及其盐的制备方法 Download PDFInfo
- Publication number
- WO2015054976A1 WO2015054976A1 PCT/CN2014/000921 CN2014000921W WO2015054976A1 WO 2015054976 A1 WO2015054976 A1 WO 2015054976A1 CN 2014000921 W CN2014000921 W CN 2014000921W WO 2015054976 A1 WO2015054976 A1 WO 2015054976A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- group
- sodium
- potassium
- reaction
- Prior art date
Links
- 0 *c1cccc(N2CCN(*)CC2)c1C=O Chemical compound *c1cccc(N2CCN(*)CC2)c1C=O 0.000 description 5
- AEOJKMCWMQHZHV-UHFFFAOYSA-N CCCCCOc1cc(NC(CC2)=O)c2cc1 Chemical compound CCCCCOc1cc(NC(CC2)=O)c2cc1 AEOJKMCWMQHZHV-UHFFFAOYSA-N 0.000 description 2
- KHOPPTSXKSJURQ-UHFFFAOYSA-N CCCCCOc1ccc(C=CC(N2)=O)c2c1 Chemical compound CCCCCOc1ccc(C=CC(N2)=O)c2c1 KHOPPTSXKSJURQ-UHFFFAOYSA-N 0.000 description 2
- KJLJAHQRPJRJEQ-UHFFFAOYSA-N O=CN(CC1)CCN1c1cccc2c1cc[s]2 Chemical compound O=CN(CC1)CCN1c1cccc2c1cc[s]2 KJLJAHQRPJRJEQ-UHFFFAOYSA-N 0.000 description 1
- JLQSJEOZDFCSNB-UHFFFAOYSA-N OC(c1cc(c(N2CCNCC2)ccc2)c2[s]1)=O Chemical compound OC(c1cc(c(N2CCNCC2)ccc2)c2[s]1)=O JLQSJEOZDFCSNB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
Definitions
- the invention belongs to the field of medicinal chemistry, and particularly relates to a preparation method of bupreazole and its analogues, key intermediates and salts thereof, and to novel compounds provided in the preparation process.
- Breproprazole (code: OPC-34712) is a new generation of antipsychotic drug candidate developed by Otsuka Pharmaceutical Co., Ltd., which acts on multiple receptors and is a partial agonist of dopamine D2 receptor (improving positive and negative symptoms, Cognitive impairment and depressive symptoms), 5-HT2A receptor antagonist (improves negative symptoms, cognitive dysfunction, symptoms of depression, insomnia), ⁇ 1 adrenergic receptor antagonist (improves positive symptoms of schizophrenia), 5 - serotonin uptake/re-uptake inhibitor (improves depressive symptoms); at the same time, 5-HT1A partial agonist (anti-anxiety and anti-depressant activity) and 5-HT7 antagonist (body temperature, circadian rhythm, learning and memory, sleep) .
- MDD major depressive disorder
- phase III clinical trials for adjuvant treatment of major depressive disorder (MDD) Phase III clinical trials for adjuvant treatment of major depressive disorder (MDD) in the United States and Europe; phase III clinical trials for the treatment of schizophrenia in the United States, Europe
- Otsuka Pharmaceutical Co., Ltd. discloses a preparation route of brieprazole in PCT application WO2006112464A1, see Reaction Formula 1.
- the difficulty of this route is that the first step reaction produces by-products which are difficult to separate, and it is difficult to obtain high purity by column chromatography. The intermediates thus affect the purity and yield of the final product brieprazole.
- Otsuka Pharmaceutical Co., Ltd. discloses another preparation method of this reaction in PCT application WO2013015456A1. See Reaction Scheme 2, the reagents used in this route are relatively expensive, high in cost, environmentally unfriendly and unsuitable for industrial large-scale production.
- an object of the present invention is to provide a new, simple, high-yield, low-cost, environmentally friendly, industrially suitable mass production of bupreazole and its analogs, key intermediates and A method for preparing the salt thereof.
- Another object of the invention is to provide novel compounds and salts thereof during the preparation process.
- the present invention provides a compound of the formula I which has the following structure:
- R is a C1 to C6 linear or branched alkyl group or a benzyl group; preferably, R is a C1 to C4 linear or branched alkyl group; most preferably, R is a methyl group, an ethyl group or a t-butyl group. base;
- R 1 is Acylamino protecting group (eg formyl) , acetyl, propionyl, benzoyl, haloacetyl, phthaloyl or alkoxycarbonyl-based amino protecting group (eg, tert-butoxycarbonyl, benzyloxycarbonyl, 9-fluorenylmethoxycarbonyl);
- the haloacetyl group is a fluoroacetyl group, a bromoacetyl group, a chloroacetyl group or an iodoacetyl group; preferably, R 1 is Formyl, acetyl and t-butoxycarbonyl;
- the invention also provides a process for the preparation of the compound of formula I, which is represented by a compound of formula II and a thiol group.
- the acetate reacts to form a compound of formula I, as shown in Reaction Scheme 3,
- X is a halogen such as fluorine, chlorine, bromine or iodine; and R and R 1 are the same as defined above for the compound of formula I;
- a base specifically, an inorganic base (for example, sodium hydroxide, potassium hydroxide, barium hydroxide, lithium hydroxide, barium hydroxide, calcium hydroxide, barium hydroxide, sodium hydrogencarbonate, Potassium hydrogencarbonate, potassium carbonate, sodium carbonate, cesium carbonate, cesium carbonate, sodium sulfide, sodium hydrogen, etc.) or an organic base (such as sodium alkoxide, potassium alkoxide, butyl lithium, 1,8-diaza heterocycle [5, 4 , 0] undecene-7 (DBU), pyridine, quinoline, 4-dimethylaminopyridine (DMAP) or an organic amine, etc.
- the sodium alkoxide may be sodium methoxide, sodium ethoxide, or propylene Sodium alkoxide, sodium isopropoxide, sodium n-butoxide, sodium t-butoxide, etc.
- the potassium alkoxide may be potassium methoxide, sodium ethoxide
- the organic amine may be triethylamine, diethylamine, tri-n-butylamine, tripropylamine, diisopropylamine, diisopropylethylamine or the like.
- the base may be an inorganic base.
- Sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium hydrogencarbonate, potassium hydrogencarbonate, potassium carbonate, sodium carbonate, cesium carbonate, sodium sulfide, sodium hydrogen, or sodium methoxide in an organic base Sodium alkoxide, potassium tert-butoxide, triethylamine, diethylamine, diisopropylamine or diisopropylethylamine;
- a suitable solvent which is water, a C 1 -C 5 lower alcohol (for example, methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, tert-butanol, n-pentyl) Alcohol, isoamyl alcohol, ethylene glycol, propylene glycol, glycerol), N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), tetrahydrofuran (THF), acetonitrile, dioxane, One or more of N-methylpyrrolidone, dichloromethane, chloroform, ethylene glycol dimethyl ether, diethylene glycol dimethyl ether or ethylene glycol monomethyl ether, etc., preferably, the solvent is water One or more of methanol, ethanol, N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO),
- the present invention also provides a compound of the formula III, which has the following structure:
- R 1 is An acylamino protecting group (such as formyl, acetyl, propionyl, benzoyl, haloacetyl, phthaloyl) or an alkoxycarbonyl amino protecting group (such as tert-butoxycarbonyl, benzyloxycarbonyl, 9-fluorenylmethoxycarbonyl), the haloacetyl group is a fluoroacetyl group, a bromoacetyl group, a chloroacetyl group or an iodoacetyl group;
- R 1 is Formyl, acetyl or tert-butoxycarbonyl
- the invention also provides a preparation method of the compound of the formula III, which is reacted with thioglycolic acid to form a compound of the formula III, which is represented by the reaction formula 4,
- X is fluorine, chlorine, bromine or iodine; and R 1 has the same meaning as defined above for the compound of formula I;
- a base specifically, an inorganic base (for example, sodium hydroxide, potassium hydroxide, barium hydroxide, lithium hydroxide, barium hydroxide, calcium hydroxide, barium hydroxide, sodium hydrogencarbonate, Potassium hydrogencarbonate, potassium carbonate, sodium carbonate, cesium carbonate, cesium carbonate, sodium sulfide, sodium hydrogen, etc.) or an organic base (such as sodium alkoxide, potassium alkoxide, butyl lithium, 1,8-diaza heterocycle [5, 4 , 0] undecene-7 (DBU), pyridine, quinoline, 4-dimethylaminopyridine (DMAP) or an organic amine, etc.
- the sodium alkoxide may be sodium methoxide, sodium ethoxide, or propylene Sodium alkoxide, sodium isopropoxide, sodium n-butoxide, sodium t-butoxide, etc.
- the potassium alkoxide may be potassium methoxide, sodium ethoxide
- the organic amine may be triethylamine, diethylamine, tri-n-butylamine, tripropylamine, diisopropylamine, diisopropylethylamine or the like.
- the base may be hydroxide in an inorganic base.
- a suitable solvent which is water, a C 1 -C 5 lower alcohol (eg methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, tert-butanol, positive Pentanol, isoamyl alcohol, ethylene glycol, propylene glycol, glycerol), N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), tetrahydrofuran (THF), acetonitrile, dioxane Or one or more of N-methylpyrrolidone, dichloromethane, chloroform, ethylene glycol dimethyl ether, diethylene glycol dimethyl ether, ethylene glycol monomethyl ether, etc., preferably, the solvent is One of water, methanol, ethanol, N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), tetrahydrofur
- the invention also relates to the following compounds:
- R 1 is an acylamino protecting group (such as formyl, acetyl, propionyl, benzoyl, haloacetyl, phthaloyl) or a benzyloxycarbonyl group of an alkoxycarbonyl amino protecting group or a 9-fluorenylmethoxycarbonyl group, the haloacetyl group being a fluoroacetyl group, a bromoacetyl group, a chloroacetyl group or an iodoacetyl group, preferably R 1 is a formyl group or an acetyl group;
- the salt is selected from the group consisting of a hydrochloride, a sulfate, a phosphate, a nitrate, an acetate, a hydrobromide, a hydroiodide, a perchlorate, a trichloroacetate, and a trifluoroacetate.
- a hydrochloride a sulfate, a phosphate, a nitrate, an acetate, a hydrobromide, a hydroiodide, a perchlorate, a trichloroacetate, and a trifluoroacetate.
- the invention also provides a process for the preparation of a compound of formula IV, which comprises the steps of obtaining a compound of formula IV by hydrolysis of a compound of formula I or a compound of formula III from formula II, and then decarboxylation to give a compound of formula IV, said method As shown in Reaction Scheme 5:
- X is fluorine, chlorine, bromine or iodine; and R 1 and R have the same meanings as defined above for the compound of formula I.
- the present invention also provides a process for preparing a critical intermediate of bupreazole or a salt thereof, which is represented by the reaction formula 6:
- R 1 is an acylamino protecting group (such as formyl, acetyl, propionyl, benzoyl, haloacetyl, phthaloyl) or an alkoxycarbonyl amino protecting group (such as t-butoxycarbonyl) , benzyloxycarbonyl, 9-fluorenylmethoxycarbonyl),
- the haloacetyl group is a fluoroacetyl group, a bromoacetyl group, a chloroacetyl group or an iodoacetyl group, preferably R 1 is a formyl group, an acetyl group, Tert-butoxycarbonyl,
- X is fluorine, chlorine, bromine or iodine;
- R is a C1 to C6 linear or branched alkyl group, benzyl group; preferably, R is a C1 to C4 linear or branched alkyl group; more preferably, R is a methyl group, an ethyl group or a t-butyl group;
- the compound of the formula III is obtained by hydrolysis of the compound of the formula I or the compound of the formula II by the reaction formula 4, followed by decarboxylation to give a compound of the formula IV, and finally the deamination protecting group to give a critical intermediate of brieprazole (a compound of the formula VI) or a salt thereof;
- the compound of formula III is first deaminated to give a compound of formula V or a salt thereof, and then decarboxylated to give a compound of formula VI or a salt thereof;
- the compound of formula III is subjected to a one-step reaction to simultaneously carry out the decarboxylation and deamination protecting groups to give a compound of formula VI or a salt thereof;
- the compound of formula I is simultaneously hydrolyzed and deprotected under acidic conditions to form a compound of formula V or a salt thereof, which is then decarboxylated to provide a compound of formula VI or a salt thereof;
- the salt of the compound of formula V and formula VI is selected from the group consisting of hydrochloride, sulfate, phosphate, nitrate
- hydrochloride sulfate, phosphate, nitrate
- an acid salt an acetate salt, a hydrobromide salt, a hydroiodide salt, a perchlorate salt, a trichloroacetate salt, and a trifluoroacetate salt
- the above salt can be alkalized according to the need to obtain Formula V and a compound of formula VI.
- the hydrolysis reaction may be carried out under acidic conditions, and the acid may be an organic acid or an inorganic acid such as sulfuric acid, hydrochloric acid, hydrogen chloride gas, hydrobromic acid, hydroiodic acid, One or more of phosphoric acid, nitric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, perchloric acid, etc., but not limited to the above-mentioned acids; it can also be carried out in the presence of a base, more specifically, in an inorganic base.
- the acid may be an organic acid or an inorganic acid such as sulfuric acid, hydrochloric acid, hydrogen chloride gas, hydrobromic acid, hydroiodic acid, One or more of phosphoric acid, nitric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, perchloric acid, etc., but not limited to the above-mentioned acids; it can also be carried out in the presence of a base,
- Potassium oxide or lithium hydroxide the hydrolysis is carried out in a suitable solvent, water, C 1 -C 5 lower alcohol (eg methanol, ethanol, n-propanol, isopropanol, n-butanol, iso Butanol, tert-butanol, n-pentanol, isoamyl alcohol, ethylene glycol, propylene glycol, glycerol), N,N-dimethylformamide (DMF), N,N-dimethylacetamide, two Sulfoxide (DMSO), tetrahydrofuran (THF), acetonitrile, dioxane, morpholine, N-methylpyrrolidone, dichloromethane, chloroform, ethylene glycol dimethyl ether, diethylene glycol dimethyl ether, B One or more of diol monomethyl ether, etc., preferably, the solvent is one or more of water, methanol, ethanol, tetrahydro
- the decarboxylation reaction can be carried out with or without a catalyst, and the catalyst can be selected from the group consisting of copper, chromite, cuprous oxide, copper oxide, chromium trioxide, cuprous bromide, cuprous chloride, chlorine.
- the solvent for the decarboxylation reaction may be selected from the group consisting of quinoline, isoquinoline, N-methylpyrrolidone (NMP), quinoxaline, ethylene glycol dimethyl ether, diphenyl ether, biphenyl, ethylene glycol, and Ethylene glycol, diethylene glycol dimethyl ether, dibut
- the deamination protecting group is carried out in the presence of an acid selected from the group consisting of hydrochloric acid, hydrogen chloride gas, Sulfuric acid, phosphoric acid, nitric acid, acetic acid, hydrobromic acid, hydroiodic acid, perchloric acid, trichloroacetic acid or trifluoroacetic acid;
- the reaction solvent is selected from the group consisting of water, dioxane, methanol, ethanol, n-propanol, isopropanol One or more of tert-butanol, diethyl ether, N-methylpyrrolidone, tetrahydrofuran, acetonitrile, dichloromethane, chloroform, N,N-dimethylformamide, ethyl acetate, propyl acetate or butyl acetate
- the above acid may be used as a reaction solvent, without adding another solvent;
- the reaction temperature is 0 ° C to 150 ° C,
- the one-step reaction simultaneously carries out the decarboxylation and deamination protecting groups in the presence of an acid selected from the group consisting of hydrochloric acid, hydrogen chloride gas, sulfuric acid, phosphoric acid, nitric acid, acetic acid, hydrobromic acid, hydroiodic acid, perchloric acid, One or more of trichloroacetic acid or trifluoroacetic acid;
- the reaction solvent is selected from the group consisting of water, dioxane, methanol, ethanol, n-propanol, isopropanol, tert-butanol, diethyl ether, N-methylpyrrolidone, One or more of tetrahydrofuran, acetonitrile, dichloromethane, chloroform, N,N-dimethylformamide, ethyl acetate, propyl acetate or butyl acetate, or the above acid may be used as a reaction solvent.
- reaction temperature is 0 ° C ⁇ 150 ° C, preferably room temperature ⁇ 100 ° C
- reaction time is 0.5 ⁇ 24 hours, preferably 1 ⁇ 12 hours
- R 1 is an alkoxycarbonyl amino protecting group (such as uncle In the case of butoxycarbonyl, benzyloxycarbonyl or 9-fluorenylmethoxycarbonyl
- the one-step reaction is carried out simultaneously with the decarboxylation and deamination protecting groups in the presence or absence of a catalyst which may be selected from the group consisting of copper and chromite.
- Acid ketone cuprous oxide, copper oxide, chromium trioxide, Cuprous, cuprous chloride, ferrous chloride, ferric chloride, copper carbonate, copper sulfate, basic copper carbonate, silver acetate, calcium oxide, calcium hydroxide, 1,8-diaza heterocycle [5, One or more of 4,0]undecene-7 (DBU), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), alumina, preferably copper, sub One or more of chromic acid ketone, cuprous oxide, copper oxide, chromium trioxide, 1,8-diazacyclo[5,4,0]undecene-7 (DBU) or alumina; Or the reaction is carried out in the presence of silver carbonate and acetic acid; the solvent of the reaction may be selected from the group consisting of quinoline, isoquinoline, N-methylpyrrolidone (NMP), quinoxaline, ethylene glycol dimethyl ether, diphenyl ether
- the acid is selected from an organic acid or an inorganic acid, such as sulfuric acid, hydrochloric acid, hydrogen chloride gas, hydrobromic acid, hydroiodic acid, phosphoric acid, nitric acid, One or more of acetic acid, trichloroacetic acid, trifluoroacetic acid, perchloric acid, etc., but not limited to the above acid;
- the reaction solvent is water, C 1 - C 5 lower alcohol (for example, methanol, ethanol, n-propanol) , isopropanol, n-butanol, isobutanol, tert-butanol, n-pentanol, isoamyl alcohol, ethylene glycol, propylene glycol, glycerol), N,N-dimethylformamide (DMF), N , one of N-dimethylacetamide, dimethyl sulfoxide (DMSO), t
- DMF N,N-dimethylformamide
- R 1 is selected from an acylamino protecting group (such as formyl ( ), acetyl, propionyl, benzoyl, haloacetyl, phthaloyl or alkoxycarbonyl amino protecting group (eg, tert-butoxycarbonyl, benzyloxycarbonyl, 9-fluorenylmethoxycarbonyl)
- an acylamino protecting group such as formyl ( ), acetyl, propionyl, benzoyl, haloacetyl, phthaloyl or alkoxycarbonyl amino protecting group (eg, tert-butoxycarbonyl, benzyloxycarbonyl, 9-fluorenylmethoxycarbonyl)
- R 1 is preferably a formyl group, an acetyl group and a tert-butoxycarbonyl group
- the reagents are inexpensive, and the reaction conditions when the protecting groups are removed are mild, and under acidic conditions
- the salt form of the compound of formula VI avoids the need for further salt formation due to base instability, reducing one-step reaction, and the entire deamination protecting group process does not require expensive reagents and special reaction equipment.
- R 1 is a benzyl group is disclosed in U.S. Patent No. 5,436,246, but the debenzylation reaction conditions are severe, requiring expensive palladium reagents and special reaction vessels, which are costly and dangerous.
- the method of the invention has the advantages of simple operation, popularization of reagents, thereby saving synthesis cost, short production cycle, improved yield and product quality, and is suitable for mass production.
- Example 1 The product of Example 1 (1.0 g, 2.5 mmol) was dissolved in 1,4-dioxane (5 mL), 4N aqueous sodium hydroxide (1.8 mL, 7.2 mmol) was added and the mixture was stirred at 80 ° C for 3 h and cooled. Water (5 mL) and ethyl acetate (10 mL) were added at room temperature, and the aqueous phase was adjusted to pH 4.0 with 1N HCl at 0 ° C. The obtained solid was filtered and dried to give a pale yellow solid.
- Example 2 The product of Example 2 (500 mg, 1.35 mmol), silver carbonate (40 mg, 0.135 mmol) and acetic acid (8 mg) were dissolved in dimethyl sulfoxide (5 mL), heated to 120 ° C, and allowed to react overnight, cooled and filtered. Water was added thereto, extracted with ethyl acetate, concentrated, and subjected to column chromatography to give the object.
- Example 3 The product of Example 3 (2 g, 6.2 mmol) was dissolved in dioxane (6 mL), and 4N HCl / dioxane solution (6 mL) was added, stirred for 3 h, then concentrated to dryness. The ethyl acetate was beaten and filtered to give the title compound (1.3 g, yield 95%).
- Example 6 The product of Example 6 (1.0 g, 3.1 mmol) was dissolved in methanol (5 mL) and water (2 mL). Ethyl acetate (10 mL) was extracted and the aqueous phase was collected. The mixture was adjusted to pH ⁇ / RTI> with <RTIgt;</RTI>
- Example 7 The product of Example 7 (1.0 g, 3.4 mmol), cuprous oxide (50 mg) was dissolved in quinoline (5 mL) and warmed to 140 ° C overnight. After cooling, it was filtered, EtOAc (EtOAc)EtOAc.EtOAc. Off-white solid (520 mg, yield 62%).
- Example 8 The product of Example 8 (500 mg) was dissolved in dioxane (2 mL), and 4N HCl / dioxane solution (3 mL) was added and stirred for 3 h, then concentrated, dried and filtered with ethyl acetate. The target (470 mg, yield 90%) was obtained.
- Example 10 The product of Example 10 (1.0 g, 3.0 mmol) was dissolved in MeOH (5 mL) and water (2 mL). The ester (10 mL) was separated, and the aqueous phase was collected. The mixture was adjusted to pH 4.0 with 1N HCl aqueous solution at 0 ° C. The precipitated solid was filtered and dried to give a pale-yellow solid (820 mg, yield 90%).
- Example 12 The product of Example 12 (1 g, 3.8 mmol) was dissolved in dioxane (6 mL), 4N HCl / dioxane (6 mL). Beating, filtration, product (870 mg, yield 90%).
- Example 2 The product of Example 2 (500 mg, 1.38 mmol) was dissolved in quinoline (3 mL), cuprous oxide (20 mg) was added, and the mixture was heated to 140 ° C for 2 h. The temperature was further increased to 240 ° C for 3 h, cooled to room temperature, and filtered. Water was added, and the mixture was extracted with ethyl acetate.
- 1 HNMR 300MHz, DMSO-d 6): ⁇ 8.74 (bs, 1H), 7.75 (d, 1H), 7.69 (d, 1H), 7.51 (d, 1H), 7.31 (t, 1H), 6.95 ( d, 1H), 3.24 (m, 8H).
- Example 2 The product of Example 2 (200 mg, 0.55 mmol) was dissolved in THF (5 mL). After cooling, methyl tert-butyl ether (5 mL) was added, and the title compound (130 mg, yield: 79%) was obtained.
- Example 20 The product of Example 20 (130 mg, 0.43 mmol) was taken in diphenyl ether (3 mL) and EtOAc After cooling, the target was obtained by filtration (60 mg, yield 55%).
- Example 25 The product of Example 25 (400 mg, 0.83 mmol), silver carbonate (46 mg, 0.16 mmol) was dissolved in EtOAc (5 mL) and EtOAc. After cooling, water was added, and the mixture was combined with EtOAc EtOAc.
- Example 17 The product of Example 17 (100 mg, 0.25 mmol) was dissolved in acetic acid (3 mL) and concentrated hydrochloric acid (0.5 In mL), stir at 100 ° C for 10 hours. The reaction solution was poured into ice water, stirred for 10 min, and filtered with suction to give the object (38 mg, yield 50%).
Abstract
Description
Claims (10)
- 根据权利要求1所述的化合物的制备方法,所述制备方法按如下反应式3进行:反应式3:其中,X为氟、氯、溴或碘;R和R1的定义如权利要求1所述;所述制备方法在碱存在下进行,优选地,所述碱为无机碱或有机碱;更优选地,所述无机碱为氢氧化钠、氢氧化钾、氢氧化锶、氢氧化锂、氢氧化钡、氢氧化钙、氢氧化铯、碳酸氢钠、碳酸氢钾、碳酸钾、碳酸钠、碳酸锶、碳酸铯、硫化钠或钠氢,所述有机碱为醇钠、醇钾、丁基锂、1,8-二氮杂环[5,4,0] 十一烯-7、吡啶、喹啉、4-二甲氨基吡啶或有机胺,其中,所述醇钠为甲醇钠、乙醇钠、丙醇钠、异丙醇钠、正丁醇钠或叔丁醇钠;所述醇钾为甲醇钾、乙醇钾、丙醇钾、异丙醇钾、正丁醇钾或叔丁醇钾,所述有机胺为三乙胺、二乙胺、三正丁胺、三丙基胺、二异丙基胺或二异丙基乙胺;最优选地,所述无机碱为氢氧化钠、氢氧化钾、氢氧化锂、碳酸氢钠、碳酸氢钾、碳酸钾、碳酸钠、碳酸锶、硫化钠或钠氢,所述有机碱为甲醇钠、乙醇钠、叔丁醇钾、三乙胺、二乙胺、二异丙基胺或二异丙基乙胺;所述制备方法在溶剂中进行;优选地,所述溶剂为选自水、C1~C5低级醇、N,N-二甲基甲酰胺、二甲亚砜、四氢呋喃、乙腈、二氧六环、N-甲基吡咯烷酮、二氯甲烷、氯仿、乙二醇二甲醚、二乙二醇二甲醚和乙二醇单甲醚中的一种或多种,所述C1~C5低级醇为甲醇、乙醇、正丙醇、异丙醇、正丁醇、异丁醇、叔丁醇、正戊醇、异戊醇、乙二醇、丙二醇或丙三醇;更优选地,所述溶剂为选自水、甲醇、乙醇、N,N-二甲基甲酰胺、二甲亚砜、四氢呋喃、乙腈、二氧六环和乙二醇二甲醚中的一种或多种;所述制备方法的反应时间为1小时~24小时,优选2小时~12小时;所述制备方法的反应温度为0℃~150℃,优选室温~100℃。
- 根据权利要求3所述的化合物的制备方法,所述制备方法按如下反应 式4进行:反应式4:其中,X为氟、氯、溴或碘;R1的定义如权利要求1所述;所述制备方法在碱存在下进行,优选地,所述碱为无机碱或有机碱;更优选地,所述无机碱为氢氧化钠、氢氧化钾、氢氧化锶、氢氧化锂、氢氧化钡、氢氧化钙、氢氧化铯、碳酸氢钠、碳酸氢钾、碳酸钾、碳酸钠、碳酸锶、碳酸铯、硫化钠或钠氢,所述有机碱为醇钠、醇钾、丁基锂、1,8-二氮杂环[5,4,0]十一烯-7、吡啶、喹啉、4-二甲氨基吡啶或有机胺,其中,所述醇钠为甲醇钠、乙醇钠、丙醇钠、异丙醇钠、正丁醇钠或叔丁醇钠;所述醇钾为甲醇钾、乙醇钾、丙醇钾、异丙醇钾、正丁醇钾或叔丁醇钾,所述有机胺为三乙胺、二乙胺、三正丁胺、三丙基胺、二异丙基胺或二异丙基乙胺;最优选地,所述无机碱为氢氧化钠、氢氧化钾、氢氧化锂、碳酸氢钠、碳酸氢钾、碳酸钾、碳酸钠、碳酸锶、硫化钠或钠氢,所述有机碱为甲醇钠、乙醇钠、叔丁醇钾、三乙胺、二乙胺、二异丙基胺或二异丙基乙胺;所述方法在溶剂中进行;优选地,所述溶剂为选自水、C1~C5低级醇、N,N-二甲基甲酰胺、二甲亚砜、四氢呋喃、乙腈、二氧六环、N-甲基吡咯烷酮、二氯甲烷、氯仿、乙二醇二甲醚、二乙二醇二甲醚和乙二醇单甲醚中的一种或多种,所述C1~C5低级醇为甲醇、乙醇、正丙醇、异丙醇、正丁醇、异丁醇、叔丁醇、正戊醇、异戊醇、乙二醇、丙二醇或丙三醇;更优选地,所述溶剂为选自水、甲醇、乙醇、N,N-二甲基甲酰胺、二甲亚砜、四氢呋喃、乙腈、二氧六环和乙二醇二甲醚中的一种或多种;所述方法的反应时间为1小时~24小时,优选2小时~12小时;所述方法的反应温度为0℃~150℃,优选室温~100℃。
- 一种制备式IV化合物的方法,所述方法包括式I化合物经水解反应或由式II化合物经权利要求4所述制备方法得到式III化合物,再经脱羧反应得到式IV化合物的步骤,其合成路径如下反应式5所示:反应式5:其中,R1和R的定义如权利要求1所述,X为氟、氯、溴、碘;所述的水解反应在酸性或碱性条件进行;优选地,所述酸为有机酸或无机酸;更优选地,所述酸为选自硫酸、盐酸、氯化氢气体、氢溴酸、氢碘酸、磷酸、硝酸、醋酸、三氯乙酸、三氟乙酸和高氯酸中的一种或多种;优选地,所述碱为无机碱或有机碱;更优选地,所述无机碱为氢氧化钠、氢氧化钾、 氢氧化锶、氢氧化锂、氢氧化钡、氢氧化钙、氢氧化铯、碳酸氢钠、碳酸氢钾、碳酸钾、碳酸钠、碳酸锶、碳酸铯、钠氢等,所述有机碱为醇钠、醇钾、丁基锂、醋酸钾、醋酸钠、1,8-二氮杂环[5,4,0]十一烯-7、吡啶、喹啉、4-二甲氨基吡啶或有机胺;其中,所述醇钠为甲醇钠、乙醇钠、丙醇钠、异丙醇钠、正丁醇钠或叔丁醇钠;所述醇钾为甲醇钾、乙醇钾、丙醇钾、异丙醇钾、正丁醇钾或叔丁醇钾;所述有机胺为三乙胺、二乙胺、三正丁胺、三丙基胺、二异丙基胺或二异丙基乙胺;最优选地,所述碱为氢氧化钠、氢氧化钾或氢氧化锂;所述水解反应在溶剂中进行,所述溶剂为选自水、C1~C5低级醇、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、二甲亚砜、四氢呋喃、乙腈、二氧六环、吗啉、N-甲基吡咯烷酮、二氯甲烷、氯仿、乙二醇二甲醚、二乙二醇二甲醚、乙二醇单甲醚中的一种或多种,其中,所述C1~C5低级醇为甲醇、乙醇、正丙醇、异丙醇、正丁醇、异丁醇、叔丁醇、正戊醇、异戊醇、乙二醇、丙二醇或丙三醇;优选地,所述溶剂为选自水、甲醇、乙醇、四氢呋喃、二氧六环中的一种或多种;所述水解反应的反应温度为0℃~200℃,优选室温~100℃;反应时间为10分钟~24小时,优选0.5~10小时;所述脱羧反应在有催化剂或无催化剂的条件下进行,所述催化剂选自铜、亚铬酸酮、氧化亚铜、氧化铜、三氧化铬、溴化亚铜、氯化亚铜、氯化亚铁、氯化铁、碳酸铜、硫酸铜、碱式碳酸铜、醋酸银、氧化钙、氢氧化钙、1,8-二氮杂环[5,4,0]十一烯-7、1,5-二氮杂二环[4.3.0]壬-5-烯、氧化铝中的一种或多种;优选地,所述催化剂选自铜、亚铬酸酮、氧化亚铜、氧化铜、三氧化铬、1,8-二氮杂环[5,4,0]十一烯-7和氧化铝中的一种或多种;或者,所述脱羧反应在碳酸银和醋酸的存在下进行;所述脱羧反应的溶剂选自喹啉、异喹啉、N-甲基吡咯烷酮、喹喔啉、乙二醇二甲醚、二苯醚、联苯、乙二醇、二乙二醇、二乙二醇二甲醚、丁醚、甲苯、二甲苯、均三甲苯、己醇、庚醇、N,N-二甲基甲酰胺、二甲亚砜、二氧六环、N,N-二甲基乙酰胺、1,3-二甲基-2-咪唑啉酮、吡啶中的一种或多种;优选地,所述溶剂选自喹啉、喹喔啉、乙二醇二甲醚、N,N-二甲基甲酰胺、二甲亚砜、二氧六环或N,N-二甲基乙酰胺中的一种或多种;所述脱羧反应的温度为室温~300℃,优选120-250℃;反应时间为5分钟~18小时。
- 一种制备式VI化合物或其盐的方法,所述方法包括以下步骤:由式I化合物进行水解反应或由式II化合物经权利要求4所述制备方法得到式III化合物,后进行脱羧反应生成式IV化合物,最后脱氨基保护基得到式VI化合物或其盐;或者,式III化合物先进行脱氨基保护基的反应得到式V化合物或其盐,再进行脱羧反应得到式VI化合物或其盐;或者,式III化合物一步反应同时进行脱羧反应和脱氨基保护基的反应得到式VI化合物或其盐;又或者,式I化合物在酸性条件下同时进行水解反应和脱氨基保护基的反应而生成式V化合物或其盐,再进行脱羧反应得到式VI化合物或其盐;式VI化合物合成路径如下反应式6所示:反应式6:其中,R1为酰基类氨基保护基(如甲酰基、乙酰基、丙酰基、苯甲酰基、卤代乙酰基、邻苯二甲酰基)或烷氧羰基类氨基保护基(如叔丁氧羰基、苄氧羰基、9-芴甲氧羰基),所述卤代乙酰基为氟代乙酰基、溴代乙酰基、氯代乙酰基或碘代乙酰基,优选R1为甲酰基、乙酰基、叔丁氧羰基,X为氟、氯、溴或碘;R为C1~C6的直链或支链烷基、苄基;优选地,R为C1~C4的直链或支链烷基;更优选地,R为甲基、乙基或叔丁基;其中,式V和式VI化合物的盐为盐酸盐、硫酸盐、磷酸盐、硝酸盐、醋酸盐、氢溴酸盐、氢碘酸盐、高氯酸盐、三氯乙酸盐或三氟乙酸盐中的一种。
- 根据权利要求8所述的方法,其中,所述的水解反应在酸性或碱性条件进行;优选地,所述酸为有机酸或无机酸;更优选地,所述酸为选自硫酸、盐酸、氯化氢气体、氢溴酸、氢碘酸、磷酸、硝酸、醋酸、三氯乙酸、三氟乙酸和高氯酸中的一种或多种;优选地,所述碱为无机碱或有机碱;更优选地,所述无机碱为氢氧化钠、氢氧化钾、氢氧化锶、氢氧化锂、氢氧化钡、氢氧化钙、氢氧化铯、碳酸氢钠、碳酸氢钾、碳酸钾、碳酸钠、碳酸锶、碳酸铯、钠氢等,所述有机碱为醇钠、醇钾、丁基锂、醋酸钾、醋酸钠、1,8-二氮杂环[5,4,0]十一烯-7、吡啶、喹啉、4-二甲氨基吡啶或有机胺;其中,所述醇钠为甲醇钠、乙醇钠、丙醇钠、异丙醇钠、正丁醇钠或叔丁醇钠;所述醇钾为甲醇钾、乙醇钾、丙醇钾、异丙醇钾、正丁醇钾或叔丁醇钾;所述有机胺为三乙胺、二乙胺、三正丁胺、三丙基胺、二异丙基胺或二异丙基乙胺;最优选地,所述碱为氢氧化钠、氢氧化钾或氢氧化锂;所述水解反应在溶剂中进行,所述溶剂为选自水、C1~C5低级醇、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、二甲亚砜、四氢呋喃、乙腈、二氧六环、吗啉、N-甲基吡咯烷酮、二氯甲烷、氯仿、乙二醇二甲醚、二乙二醇二甲醚、乙二醇单甲醚中的一种或多种,其中,所述C1~C5低级醇为甲醇、乙醇、正丙醇、异丙醇、正丁醇、异丁醇、叔丁醇、正戊醇、异戊醇、乙二醇、丙二醇或丙三醇;优选地,所述溶剂为选自水、甲醇、乙醇、四氢呋喃、二氧六环中的一种或多种;所述水解反应的反应温度为0℃~200℃,优选室温~100℃;反应时间为10分钟~24小时,优选0.5~10小时;所述脱羧反应在有催化剂或无催化剂的条件下进行,所述催化剂选自铜、亚铬酸酮、氧化亚铜、氧化铜、三氧化铬、溴化亚铜、氯化亚铜、氯化亚铁、氯化铁、碳酸铜、硫酸铜、碱式碳酸铜、醋酸银、氧化钙、氢氧化钙、1,8- 二氮杂环[5,4,0]十一烯-7、1,5-二氮杂二环[4.3.0]壬-5-烯、氧化铝中的一种或多种;优选地,所述催化剂选自铜、亚铬酸酮、氧化亚铜、氧化铜、三氧化铬、1,8-二氮杂环[5,4,0]十一烯-7和氧化铝中的一种或多种;或者,所述脱羧反应在碳酸银和醋酸的存在下进行;所述脱羧反应的溶剂选自喹啉、异喹啉、N-甲基吡咯烷酮、喹喔啉、乙二醇二甲醚、二苯醚、联苯、乙二醇、二乙二醇、二乙二醇二甲醚、丁醚、甲苯、二甲苯、均三甲苯、己醇、庚醇、N,N-二甲基甲酰胺、二甲亚砜、二氧六环、N,N-二甲基乙酰胺、1,3-二甲基-2-咪唑啉酮、吡啶中的一种或多种;优选地,所述溶剂选自喹啉、喹喔啉、乙二醇二甲醚、N,N-二甲基甲酰胺、二甲亚砜、二氧六环或N,N-二甲基乙酰胺中的一种或多种;所述脱羧反应的温度为室温~300℃,优选120-250℃;反应时间为5分钟~18小时;所述脱氨基保护基的反应在酸存在下进行;优选地,所述酸选自盐酸、氯化氢气体、硫酸、磷酸、硝酸、醋酸、氢溴酸、氢碘酸、高氯酸、三氯乙酸和三氟乙酸中的一种或多种;所述脱氨基保护剂的反应的溶剂选自水、二氧六环、甲醇、乙醇、正丙醇、异丙醇、叔丁醇、乙醚、N-甲基吡咯烷酮、四氢呋喃、乙腈、二氯甲烷、氯仿、N,N-二甲基甲酰胺、乙酸乙酯、乙酸丙酯和乙酸丁酯中的一种或多种;或者所述溶剂为选自盐酸、硫酸、磷酸、硝酸、醋酸、氢溴酸、氢碘酸、高氯酸、三氯乙酸和三氟乙酸中的一种或多种;所述脱氨基保护基的反应温度为0℃~150℃,优选室温~100℃;反应时间为0.5~24小时,优选1~12小时;所述的一步反应同时进行脱羧反应和脱氨基保护基的反应在酸存在下进行,所述的酸为盐酸、氯化氢气体、硫酸、磷酸、硝酸、醋酸、氢溴酸、氢碘酸、高氯酸、三氯乙酸或三氟乙酸中的一种或多种;所述反应溶剂选自水、二氧六环、甲醇、乙醇、正丙醇、异丙醇、叔丁醇、乙醚、N-甲基吡咯烷酮、四氢呋喃、乙腈、二氯甲烷、氯仿、N,N-二甲基甲酰胺、乙酸乙酯、乙酸丙酯和乙酸丁酯中的一种或多种;或者所述溶剂为盐酸、硫酸、磷酸、硝酸、醋酸、氢溴酸、氢碘酸、高氯酸、三氯乙酸或三氟乙酸中的一种或多种;反应温度为0℃~150℃,优选室温~100℃;反应时间为0.5~24小时,优选1~12小时;或者,当R1为烷氧羰基类氨基保护基(如叔丁氧羰基、苄氧羰基或9-芴甲氧羰基)时,所述的一步反应同时进行脱羧反应和脱氨基保护基的反应在有催化剂或无催化剂的条件下进行,所述催化剂选自铜、亚铬酸酮、氧化亚 铜、氧化铜、三氧化铬、溴化亚铜、氯化亚铜、氯化亚铁、氯化铁、碳酸铜、硫酸铜、碱式碳酸铜、醋酸银、氧化钙、氢氧化钙、1,8-二氮杂环[5,4,0]十一烯-7、1,5-二氮杂二环[4.3.0]壬-5-烯、氧化铝中的一种或多种;优选地,所述催化剂选自铜、亚铬酸酮、氧化亚铜、氧化铜、三氧化铬、1,8-二氮杂环[5,4,0]十一烯-7和氧化铝中的一种或多种;或者,所述反应在碳酸银和醋酸存在下进行;所述反应的溶剂选自喹啉、异喹啉、N-甲基吡咯烷酮、喹喔啉、乙二醇二甲醚、二苯醚、联苯、乙二醇、二乙二醇、二乙二醇二甲醚、丁醚、甲苯、二甲苯、均三甲苯、己醇、庚醇、N,N-二甲基甲酰胺、二甲亚砜、二氧六环、N,N-二甲基乙酰胺、1,3-二甲基-2-咪唑啉酮、吡啶中的一种或多种;优选喹啉、喹喔啉、乙二醇二甲醚、N,N-二甲基甲酰胺、二甲亚砜、二氧六环或N,N-二甲基乙酰胺中的一种或多种;反应温度为室温~300℃,优选120-250℃;反应时间为5分钟~18小时;所述的在酸性条件下同时进行水解反应和脱氨基保护基的反应步骤中,所述酸为有机酸或无机酸;优选地,所述酸选自硫酸、盐酸、氯化氢气体、氢溴酸、氢碘酸、磷酸、硝酸、醋酸、三氯乙酸、三氟乙酸、高氯酸中的一种或多种;所述反应溶剂选自水、C1~C5低级醇、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、二甲亚砜、四氢呋喃、乙腈、二氧六环、吗啉、N-甲基吡咯烷酮、乙酸乙酯和二氯甲烷中的一种或多种;其中,所述C1~C5低级醇为甲醇、乙醇、正丙醇、异丙醇、正丁醇、异丁醇、叔丁醇、正戊醇、异戊醇、乙二醇、丙二醇或丙三醇;或者所述反应溶剂选自硫酸、盐酸、氢溴酸、氢碘酸、磷酸、硝酸、醋酸、三氯乙酸、三氟乙酸、高氯酸中的一种或多种;反应温度为0℃~200℃,优选室温~100℃;反应时间为0.5~24小时,优选1~12小时。
- 根据权利要求1、3所述的化合物以及式II所示的化合物在制备式IV所示化合物中的用途;根据权利要求1、3、5或7所述的化合物以及式II所示的化合物在制备式VI所示化合物中的用途。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/030,331 US10100044B2 (en) | 2013-10-18 | 2014-10-20 | Methods for preparing brexpiprazole, key intermediates thereof and salts thereof |
EP14854084.2A EP3059237A1 (en) | 2013-10-18 | 2014-10-20 | Methods for preparing brexpiprazole, key intermediates thereof and salts thereof |
JP2016548404A JP6188960B2 (ja) | 2013-10-18 | 2014-10-20 | ブレクスピプラゾール、重要な中間体およびその塩の製造方法 |
CN201480039363.4A CN105473579B (zh) | 2013-10-18 | 2014-10-20 | 布瑞哌唑、其关键中间体及其盐的制备方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310493206.8 | 2013-10-18 | ||
CN201310493206.8A CN104557896A (zh) | 2013-10-18 | 2013-10-18 | 布瑞哌唑、其关键中间体及其盐的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015054976A1 true WO2015054976A1 (zh) | 2015-04-23 |
Family
ID=52827618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2014/000921 WO2015054976A1 (zh) | 2013-10-18 | 2014-10-20 | 布瑞哌唑、其关键中间体及其盐的制备方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US10100044B2 (zh) |
EP (1) | EP3059237A1 (zh) |
JP (1) | JP6188960B2 (zh) |
CN (2) | CN104557896A (zh) |
WO (1) | WO2015054976A1 (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017025987A1 (en) * | 2015-08-11 | 2017-02-16 | Mylan Laboratories Limited | Process for the preparation of brexpiprazole |
EP3150591A1 (en) | 2015-10-02 | 2017-04-05 | Crystal Pharma S.A.U | Process and intermediates for the preparation of benzo[b]thiophene compounds |
WO2017078621A1 (en) * | 2015-11-03 | 2017-05-11 | Scinopharm Taiwan, Ltd. | Processes for preparing brexpiprazole |
WO2017115287A1 (en) | 2015-12-28 | 2017-07-06 | Honour (R&D) | Process for the preparation of quinoline-2(1h)-one derivatives |
US10358440B2 (en) | 2016-05-03 | 2019-07-23 | Cadila Healthcare Limited | Process for the preparation of brexpiprazole and intermediates thereof |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105732572A (zh) * | 2014-12-10 | 2016-07-06 | 苏州鹏旭医药科技有限公司 | 一种Brexpiprazole中间体的制备方法及Brexpiprazole中间体 |
CN105985314A (zh) * | 2015-02-05 | 2016-10-05 | 苏州旺山旺水生物医药有限公司 | 布瑞哌唑类似物的制备方法 |
CN104844586A (zh) * | 2015-04-16 | 2015-08-19 | 重庆医药工业研究院有限责任公司 | 一种依匹哌唑无定型物及其制备方法 |
CN104829588B (zh) * | 2015-04-30 | 2017-03-29 | 苏州苏旺森生物医药科技有限公司 | 一种苯并[b]噻吩的制备方法及其中间体 |
CN105061414B (zh) * | 2015-07-21 | 2019-01-01 | 杭州新博思生物医药有限公司 | 一锅法制备Brexpiprazole |
CN105461704A (zh) * | 2015-12-15 | 2016-04-06 | 南京艾德凯腾生物医药有限责任公司 | 一种依匹哌唑的制备方法 |
CN106938982A (zh) * | 2016-01-05 | 2017-07-11 | 连云港皓海医药科技有限公司 | 布瑞哌唑的制备方法及用于制备布瑞哌唑的化合物 |
CN105399736B (zh) * | 2016-01-07 | 2018-10-19 | 安徽省逸欣铭医药科技有限公司 | 一种依匹哌唑新的制备方法 |
CN106645494B (zh) * | 2016-12-29 | 2019-09-06 | 成都百裕制药股份有限公司 | 依匹哌唑起始物料有关物质的检测方法 |
CN109694343B (zh) * | 2018-12-19 | 2020-07-28 | 帕潘纳(北京)科技有限公司 | 一种杂环羧酸类化合物的脱羧方法 |
CN110483475B (zh) * | 2019-08-15 | 2020-11-27 | 绍兴文理学院 | 一种氧化银催化法制备苯并噻吩类化合物的方法 |
CN110483476B (zh) * | 2019-08-15 | 2020-11-27 | 绍兴文理学院 | 一种催化法制备苯并硒吩类化合物的工艺 |
CN111423452B (zh) * | 2020-03-26 | 2023-08-22 | 江西青峰药业有限公司 | 瑞卢戈利的中间体及其制备方法和应用 |
CN115894435A (zh) * | 2022-11-14 | 2023-04-04 | 山东厚德精诚药业有限公司 | 一种1-(苯并[b]噻吩-4-基)哌嗪盐酸盐的合成方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5436246A (en) | 1992-09-17 | 1995-07-25 | Merrell Dow Pharmaceuticals Inc. | Serotonin receptor agents |
WO2006112464A1 (en) | 2005-04-14 | 2006-10-26 | Otsuka Pharmaceutical Co., Ltd. | Piperazine-substituted benzothiophenes for treatment of mental disorders |
WO2009128537A1 (ja) * | 2008-04-18 | 2009-10-22 | 大塚製薬株式会社 | 複素環化合物 |
WO2013015456A1 (en) | 2011-07-28 | 2013-01-31 | Otsuka Pharmaceutical Co., Ltd. | Method for producing benzo[b]thiophene compound |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4977154A (en) * | 1985-12-12 | 1990-12-11 | Warner-Lambert Company | 5-amino and 5-hydroxy-6-fluoroquinolones as antibacterial agents |
KR20070041762A (ko) * | 2004-07-28 | 2007-04-19 | 글락소 그룹 리미티드 | 위장관 장애의 치료에 유용한 피페라진 유도체 |
JP4315393B2 (ja) * | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
JP4540700B2 (ja) * | 2006-10-13 | 2010-09-08 | 大塚製薬株式会社 | 医薬 |
CN104892589A (zh) * | 2014-03-07 | 2015-09-09 | 中国科学院上海药物研究所 | 一类杂环化合物、其制备方法和用途 |
-
2013
- 2013-10-18 CN CN201310493206.8A patent/CN104557896A/zh active Pending
-
2014
- 2014-10-20 JP JP2016548404A patent/JP6188960B2/ja active Active
- 2014-10-20 CN CN201480039363.4A patent/CN105473579B/zh active Active
- 2014-10-20 EP EP14854084.2A patent/EP3059237A1/en not_active Withdrawn
- 2014-10-20 US US15/030,331 patent/US10100044B2/en not_active Expired - Fee Related
- 2014-10-20 WO PCT/CN2014/000921 patent/WO2015054976A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5436246A (en) | 1992-09-17 | 1995-07-25 | Merrell Dow Pharmaceuticals Inc. | Serotonin receptor agents |
WO2006112464A1 (en) | 2005-04-14 | 2006-10-26 | Otsuka Pharmaceutical Co., Ltd. | Piperazine-substituted benzothiophenes for treatment of mental disorders |
WO2009128537A1 (ja) * | 2008-04-18 | 2009-10-22 | 大塚製薬株式会社 | 複素環化合物 |
WO2013015456A1 (en) | 2011-07-28 | 2013-01-31 | Otsuka Pharmaceutical Co., Ltd. | Method for producing benzo[b]thiophene compound |
Non-Patent Citations (1)
Title |
---|
See also references of EP3059237A4 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017025987A1 (en) * | 2015-08-11 | 2017-02-16 | Mylan Laboratories Limited | Process for the preparation of brexpiprazole |
EP3150591A1 (en) | 2015-10-02 | 2017-04-05 | Crystal Pharma S.A.U | Process and intermediates for the preparation of benzo[b]thiophene compounds |
WO2017055543A1 (en) | 2015-10-02 | 2017-04-06 | Crystal Pharma, S.A.U. | Process and intermediates for the preparation of benzo[b]thiophene compounds |
JP2018529727A (ja) * | 2015-10-02 | 2018-10-11 | クリスタル ファルマ、エセ、ア、ウCrystal Pharma,S.A.U. | ベンゾ[b]チオフェン化合物を製造するための方法および中間体 |
US10597386B2 (en) | 2015-10-02 | 2020-03-24 | Crystal Pharma, S.A.U. | Process and intermediates for the preparation of benzo[b]thiophene compounds |
US11312708B2 (en) | 2015-10-02 | 2022-04-26 | Crystal Pharma, S.A.U. | Process and intermediates for the preparation of benzo[b]thiophene compounds |
WO2017078621A1 (en) * | 2015-11-03 | 2017-05-11 | Scinopharm Taiwan, Ltd. | Processes for preparing brexpiprazole |
WO2017115287A1 (en) | 2015-12-28 | 2017-07-06 | Honour (R&D) | Process for the preparation of quinoline-2(1h)-one derivatives |
US10358440B2 (en) | 2016-05-03 | 2019-07-23 | Cadila Healthcare Limited | Process for the preparation of brexpiprazole and intermediates thereof |
Also Published As
Publication number | Publication date |
---|---|
US10100044B2 (en) | 2018-10-16 |
EP3059237A4 (en) | 2016-08-24 |
JP6188960B2 (ja) | 2017-08-30 |
JP2016535081A (ja) | 2016-11-10 |
CN104557896A (zh) | 2015-04-29 |
CN105473579A (zh) | 2016-04-06 |
EP3059237A1 (en) | 2016-08-24 |
US20160272624A1 (en) | 2016-09-22 |
CN105473579B (zh) | 2018-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015054976A1 (zh) | 布瑞哌唑、其关键中间体及其盐的制备方法 | |
EP3372606B1 (en) | Crystal form, preparation method and intermediate of dihydropyrido ring compound | |
CN111386272B (zh) | 一种改进的瑞博西尼及其盐的制备方法 | |
JP2016535081A5 (zh) | ||
US11246862B2 (en) | Process for the preparation of lifitegrast | |
ES2769255T3 (es) | Métodos para fabricar inhibidores de la proteína desacetilasa | |
WO2022018625A1 (en) | Process for the preparation of an intermediate used in the synthesis of letermovir | |
WO2020108522A1 (zh) | 一种氘代大环化合物的制备方法 | |
WO2018082441A1 (zh) | 4-亚甲基哌啶或其酸加成盐的制备方法 | |
KR20180005214A (ko) | 질소 머스타드 유도체의 제조 방법 | |
WO2016124144A1 (zh) | 布瑞哌唑类似物的制备方法 | |
US9006423B2 (en) | Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof | |
US8519176B1 (en) | Process for preparation of substituted P-aminophenol | |
US20240059678A1 (en) | Synthesis Method for Aminopyrimidine FAK Inhibitor Compound | |
CN107722007B (zh) | 阿哌沙班杂质的制备方法 | |
NZ554731A (en) | Novel Intermediates Useful For The Preparation Of Aripiprazole And Methods For The Preparation Of The Novel Intermediates And Aripiprazole | |
WO2016034150A1 (zh) | 博舒替尼及其结晶的制备方法 | |
EP3305780A1 (en) | Method for the preparation of h-arg(mis)-oh | |
KR101896349B1 (ko) | 디미라세탐의 제조 방법 | |
CN108239141A (zh) | 一种阿拉莫林的制备方法 | |
EP4229054A1 (en) | Process for the preparation of 1-methyl-6-[6-r2-5-methyl-8-(methylamino)-4-[ (3as,6as)-5-methyl-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrol-1-yl]-9h-pyrido[2,3-b]indol-3-yl]-4-oxo-1,8-naphthyridine-3-carboxylic acid hydrochloride | |
CN115785081A (zh) | 一种雷替曲塞的制备方法 | |
US20190359553A1 (en) | A process for the preparation of phenoxybenzamine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480039363.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14854084 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016548404 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15030331 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2014854084 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014854084 Country of ref document: EP |